Clonazepam Clonazepam 0.5 MG Oral Tablet
INDICATIONS AND USAGE Seizure Disorders Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam tablets, USP may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: Loss of Effect ). Panic Disorder Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam tablets, USP was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-V) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam tablets, USP in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam tablets, USP for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ).
Eon Labs, Inc.
ROUND YELLOW E 63
E 63 ROUND YELLOW
Related Pills
clonazepam tablet
eon labs, inc.
Clonazepam Clonazepam 1 MG Oral Tablet
Eon Labs, Inc.
Clonazepam Clonazepam 0.5 MG Oral Tablet
Eon Labs, Inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
HOW SUPPLIED Clonazepam Tablets, USP, for oral administration, are available as: 0.5 mg : round, light yellow, bi-convex tablet, debossed “ E ” over “63” on one side and bisected on the other side and supplied as: NDC 0185-0063-01 bottles of 100 NDC 0185-0063-05 bottles of 500 NDC 0185-0063-10 bottles of 1000 0.5 mg : round, light yellow, flat-faced beveled edge, debossed “ E ” over “63” on one side and bisected on the reverse side and supplied as: NDC 0781-8018-01 bottles of 100 NDC 0781-8018-05 bottles of 500 NDC 0781-8018-10 bottles of 1000 1 mg : round, light blue, bi-convex tablet, debossed “ E ” over “64” on one side and bisected on the other side and supplied as: NDC 0185-0064-01 bottles of 100 NDC 0185-0064-05 bottles of 500 NDC 0185-0064-10 bottles of 1000 1 mg : round, light blue, bi-convex tablet, debossed “ E ” over “64” on one side and plain on the reverse side and supplied as: NDC 0781-5567-01 bottles of 100 NDC 0781-5567-05 bottles of 500 NDC 0781-5567-10 bottles of 1000 2 mg : round, white, bi-convex tablet, debossed “ E ” over “65” on one side and bisected on the other side and supplied as: NDC 0185-0065-01 bottles of 100 NDC 0185-0065-05 bottles of 500 NDC 0185-0065-10 bottles of 1000 2 mg : round, white, bi-convex tablet, debossed “ E ” over “65” on one side and plain on the reverse side and supplied as: NDC 0781-5569-01 bottles of 100 NDC 0781-5569-05 bottles of 500 NDC 0781-5569-10 bottles of 1000 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure, as required. KEEP TIGHTLY CLOSED. KEEP OUT OF THE REACH OF CHILDREN. Manufactured by Sandoz Inc. Princeton, NJ 08540
More pills like ROUND E 63